Acceleron Pharma — Investor Presentation (January 2019)
39 slides from Acceleron Pharma's investor presentation, Jan 7, 2019
Slide 1: Corporate Presentation
Exhibit 99.1 Corporate Presentation January 7, 2019 1
Slide 2: Forward-Looking Statements
Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY’S STRATEGY, FUTURE PLANS and prospects, including statements regarding the development of the Company's compounds, the timeline for clinical development and regulatory approval of the Company
Slide 3: Mission and Therapeutic Area Focus
Mission and Therapeutic Area Focus HEMATOLOGY Our mission is to transform the lives NEUROMUSCULAR of patients with serious and rare diseases PULMONARY 3
Slide 4: Building Therapeutic Area Leadership
Building Therapeutic Area Leadership HematologyHHematollogy HEMATOLOGY NEUROMUSCULAR PULMONARY LuspaterceptLusppaterceptp Phase 3 Trials--Luspatercept Phase 2 Trials Phase 2 Trials--Sotatercept Lower-Risk MDS, RS+ ACE-083 Facioscapulohumeral muscular dystrophy (FSHD) Pulmonary arterial hypertension
Slide 5: 2018 Key Milestones Across Therapeutic Areas
2018 Key Milestones Across Therapeutic Areas Luspatercept ACE-083 Sotatercept Positive MEDALIST and BELIEVE Positive Part 1 results in CMT and PULSAR Phase 2 trial initiated Phase 3 trial results FSHD Phase 2 trials Multiple preclinical presentations ASH 2018 – MEDALIST and Presentations at multiple
Slide 6: Anemia impacts approximately 25% of the population
Anemia impacts approximately 25%1 of the population, or >1.5b people worldwide Hematology 1. de Benoist B et al., eds. Worldwide prevalence of anaemia 1993-2005. WHO Global Database on Anaemia Geneva, World Health Organization, 2008
Slide 7: Chronic Anemia Due to Rare Blood Disorders
Chronic Anemia Due to Rare Blood Disorders LOWER-RISK MDS Bone marrow failure disorder BETA-THALASSEMIA CHRONIC Genetic hemoglobin mutation ANEMIA MYELOFIBROSIS Fibrotic bone marrow disease 7
Slide 8: Anemia's Impact on Patients
Anemia’s Impact on Patients Fatigue/tiredness/weaknessdness/weakness Shortness off breathbreath/dizziness/dizziness Reduced mentalntal sharpnesssharpness Impact on dailyaily activitactivityy level Regular red bbloodlood cell transfusions 8
Slide 9: Burden of Red Blood Cell Transfusion
Burden of Red Blood Cell Transfusion Process Blood donation Processing, testing, Storage Distribution & packaging 6ම ĨŽƌчϰϮĚĂLJƐ Patient with chronic Red Blood Cell Iron Overload anemia hits Cross-match Transfusion Infection hemoglobin threshold Appointment Decreased Mortality Appointment Alloim
Slide 10: Lack of Viable Treatment Options
Lack of Viable Treatment Options 1989 > 30 years 2020 Synthetic Potential erythropoietin No new product approvals to treat Luspatercept approved for lower-risk MDS-, beta-thalassemia-, and/or U.S. / E.U. market certain anemias myelofibrosis-associated anemia in the U.S. approval 10
Slide 11: Luspatercept: A First-in-Class Erythroid Maturation Agent
Luspatercept: A First-in-Class Erythroid Maturation Agent 6WHP 3URJHQLWRU &HOO &HOOV (U\WKUREODVWPDWXUDWLRQLQWRUHGEORRGFHOOV TGF-BETA PROTEINS LUSPATERCEPT 11
Slide 12: MEDALIST and BELIEVE Phase 3 Trial Results
MEDALIST and BELIEVE Phase 3 Trial Results Phase 3 Phase 3 Lower-Risk MDS, RS+ ɴ-Thalassemia, Transfusion-Dependent ƒ ASH 2018 plenary and oral presentations selected for “Best of ASH” ƒ Luspatercept met all primary and key secondary endpoints ƒ Durable responses with a favorable safety profile ƒ Pl
Slide 13: Additional Luspatercept Trials Underway
Additional Luspatercept Trials Underway Phase 3 Phase 2 Phase 2 Lower-Risk MDS, First-line ɴ-Thalassemia, Non- Transfusion-Dependent ƒ Enrolling up to 350 ƒ Enrolling up to 150 ƒ Enrolling up to 70 patients patients patients New trials supported by Phase 2 results 56%1 53%2 шϯϬй3 RBC Transfusion Ind
Slide 14: A Potential Platform Treatment for Chronic Anemias
A Potential Platform Treatment for Chronic Anemias Evaluating additional Lower-Risk MDS Lower-Risk MDS ɴ-Thalassemia ɴ-Thalassemia, diseases RS+ First-line Transfusion-Dependent Non-Transfusion- associated with Dependent anemia $2 Billion + $1 Billion + + TBD Estimated Estimated Annual Peak Annual P
Slide 15: Luspatercept's Potential Revenue Drives Significant Value
Luspatercept’s Potential Revenue Drives Significant Value Acceleron Receives Royalty % Low to Mid-20s Celgene Funds Program Costs ~100% Potential Acceleron Annual Royalty Revenue Annual Peak Sales Potential Scenarios 15
Slide 16: Neuromuscular Disease
ly Vy Neuromuscular Disease
Slide 17: ACE-083: Targeting Focal Muscle Disease
ACE-083: Targeting Focal Muscle Disease Administered into target Facioscapulohumeral Charcot-Marie-Tooth muscle for concentrated effect Muscular Dystrophy (FSHD) Disease (CMT) ACE-083 Myopathy Neuropathy Locally-acting ƒ 20,000 U.S. patients ƒ > 100,000 U.S. patients myostatin+ 17
Slide 18: High Unmet Medical Need in FSHD and CMT
High Unmet Medical Need in FSHD and CMT ƒ Slowly progressing muscle weakness diseases – Patients are typically diagnosed at a young age (20s to 30s) – Muscle weakness can progress asymmetrically ƒ No approved pharmacology solutions – Treatment is currently limited to physical therapy and bracing ƒ F
Slide 19: Two-Part Phase 2 Trials in FSHD and CMT
Two-Part Phase 2 Trials in FSHD and CMT PART 1 RESULTS ƒ Mean total muscle volume increases (14% to 20%)* ƒ Reduction in absolute fat fraction (overall muscle quality improvement)* ƒ No serious adverse events, most common adverse events were mild or moderate (grades 1-2)* PART 2FSHD* OF EACH PHASE 2
Slide 20: Pulmonary Disease
Pulmonary Disease
Slide 21: Pulmonary Arterial Hypertension (PAH) Disease Background
Pulmonary Arterial Hypertension (PAH) Disease Background Symptoms PATIENT SNAPSHOT mean ƒ Shortness of breath age 50 ƒ Chest pain ƒ Dizziness and/or fainting 3 to 1 ƒ Exertion fatigue 70K women to men U.S./E.U. PAH Patients 21
Slide 22: Current Therapies Are Not Enough
Current Therapies Are Not Enough DRUG APPROVALS 14 disease modifying over the last 20 YEARS NO therapies Improved survival and quality of life Median survival ~5 to 7 years 22
Slide 23: PAH: A Disease of Vascular Remodeling
PAH: A Disease of Vascular Remodeling Pulmonary Arteries Elevated pressure in the pulmonary circulation leads to heart failure Normal Arterial Hypertension • Smooth muscle cell hypertrophy • Endothelial cell proliferation • Intimal fibrosis 23
Slide 24: Sotatercept's Activity in Preclinical Studies
Sotatercept’s Activity in Preclinical Studies Sotatercept1 Preclinical Study: Sugen Hypoxia Model Lung histology Pulmonary Arterioles (10-50 μm, N=100) Classification (%)2 ;ɲ^DͬĞůĂƐƚŝŶƐƚĂŝŶŝŶŐ͕ϭϬyŵĂŐŶŝĨŝĐĂƚŝŽŶͿ % of Completely Muscularized Vessels 72.5% 29.3% Vehicle Sotatercept1 Vehicle Sotater
Slide 25: PAH Phase 2 Trials Ongoing and Planned
PAH Phase 2 Trials Ongoing and Planned Traditional Phase 2 Trial Exploratory Phase 2 Trial Randomized, double blind, placebo-controlled Open-label, single arm N = 100 N = 25 6-month primary treatment period: 6-month primary treatment period endpoints: ƒ Primary endpoint: pulmonary vascular resistanc
Slide 26: Upcoming Corporate Priorities
Upcoming Corporate Priorities HEMATOLOGY ƒ Luspatercept – Planned marketing authorization applications in US and EU for LR MDS and ɴ-thalassemia in 1H 2019 – MEDALIST and BELIEVE Phase 3 trial results planned to be submitted for publication in 2019 – COMMANDS Phase 3 clinical trial patient enrollmen
Slide 27: Long-term Vision for Growth and Value Creation
Long-term Vision for Growth and Value Creation ACE-083 (2019) Sotatercept (2020) • Phase 2 results expected in • PULSAR & SPECTRA Phase Luspatercept (2018) FSHD & CMT 2 results expected in PAH • Positive MEDALIST and BELIEVE Phase 3 trial results • COMMANDS and BEYOND trials initiated • Myelofibrosi
Slide 28: Additional Slides
Additional Slides
Slide 29: ASH 2018: MEDALIST and BELIEVE Phase 3 Trial Results
ASH 2018: MEDALIST and BELIEVE Phase 3 Trial Results 29
Slide 30: MEDALIST Phase 3 Trial Design
MEDALIST Phase 3 Trial Design Double-blind Screening Week 24 Week 48 luspatercept 16-week Treated Lower- confirmed SC Primary Secondary Risk MDS transfusion Every 3 Endpoint Endpoint burden Weeks (RS+) Placebo 2:1 Randomized ƒ Primary Endpoint – RBC-ƚƌĂŶƐĨƵƐŝŽŶŝŶĚĞƉĞŶĚĞŶĐĞ;шϴǁĞĞŬƐͿĚƵƌŝŶŐƚŚĞĨŝ
Slide 31: MEDALIST Phase 3 Trial Primary Endpoint
MEDALIST Phase 3 Trial Primary ŶĚƉŽŝŶƚ͗ZĞĚůŽŽĚĞůůdƌĂŶƐĨƵƐŝŽŶ/ŶĚĞƉĞŶĚĞŶĐĞшϴtĞĞŬƐ Luspatercept Placebo RBC-d/шϴǁĞĞŬƐ (n = 153) (n = 76) Weeks 1–24, n (%) 58 (37.9) 10 (13.2) 95% CI 30.2–46.1 6.5–22.9 P valuea < 0.0001 a Cochran–Mantel–Haenszel test stratified for average baseline RBC tr
Slide 32: MEDALIST Secondary Endpoint: Erythroid Response (HI-E)
MEDALIST Phase 3 Trial Secondary Endpoint: Erythroid Response (HI-E) Luspatercept Placebo (n = 153) (n = 76) Achieved HI-Ea (weeks 1–24), n (%) 81 (52.9) 9 (11.8) Reduction of ш4 RBC units/8 weeks (baseline transfusion burden ш4 units/8 weeks) 52/107 (48.6) 8/56 (14.3) ,ďŝŶĐƌĞĂƐĞŽĨшϭ͘ϱŐͬĚ> (b
Slide 33: BELIEVE Phase 3 Trial Design
BELIEVE Phase 3 Trial Design Double-blind Weeks Weeks Screening 13 - 24 37 - 48 12-week luspatercept Treated prospective ɴ-Thalassemia SC Primary Secondary pre- Every 3 Endpoint Transfusion- treatment Endpoint Weeks Dependent period Placebo 2:1 Randomized ƒ Primary Endpoint – шϯϯйƌĞĚƵĐƚŝŽŶŝŶƚƌĂŶ
Slide 34: BELIEVE Primary endpoint MET: Rate of Erythroid Response
BELIEVE Phase 3 Trial Primary endpoint MET: Rate of Erythroid Response A significantly greater proportion of luspatercept-WUHDWHGSDWLHQWVDFKLHYHGD•UHGXFWLRQIURP baseline in transfusion burden during weeks 13 to 24 30 Luspatercept P < 0.0001 (OR 5.79, 95% CI 2.24–14.97) Placebo 25 20 15 21
Slide 35: BELIEVE All key secondary endpoints MET
BELIEVE Phase 3 Trial All key secondary endpoints MET: Rates of Erythroid Response A significantly greater proportion of luspatercept-treated patients achieved clinically meaningful reductions in WUDQVIXVLRQEXUGHQRI•DQG• 30 Luspatercept P < 0.0001a 25 Placebo 20 P = 0.0017c 15 P = 0.030
Slide 36: BELIEVE Reduction in transfusion burden during any 12- and 24-week interval
BELIEVE Phase 3 Trial Reduction in transfusion burden during ANY 12- and 24-week interval During any 12- or 24-week interval, a significantly greater proportion of luspatercept-treated patients DFKLHYHGFOLQLFDOO\PHDQLQJIXOUHGXFWLRQVLQWUDQVIXVLRQEXUGHQRI•DQG• Any 12-week interval An
Slide 37: COMMANDS Phase 3 Trial Design
COMMANDS Phase 3 Trial Design Open-label Screening luspatercept Weeks 0 - 24 Weeks 0 - 48 16-week (n = 175) Primary/ First-line, confirmed Secondary Secondary Lower- transfusion Endpoints Endpoints Risk MDS history epoetin alfa (n = 175) 1:1 Randomized ƒ Primary Endpoint – RBC-transfusion independen
Slide 38: BEYOND Phase 2 Trial Design
BEYOND Phase 2 Trial Design Double-blind Screening luspatercept Weeks 13 - 24 Weeks 37 - 48 (n = 100) ɴ-Thalassemia 4-week Primary Secondary Non-Transfusion- period Endpoint Endpoint Dependent Placebo (n = 50) 2:1 Randomized ƒ Primary Endpoint – WƌŽƉŽƌƚŝŽŶŽĨƉĂƚŝĞŶƚƐǁͬĐŽŶƚŝŶƵŽƵƐŝŶĐƌĞĂƐĞшϭ͘ϬŐͬ
Slide 39: Myelofibrosis Phase 2 Trial Design
Myelofibrosis Phase 2 Trial Design Luspatercept Monotherapy Cohort 1: Anemia Only (n = 20) 24 WEEKS ƒ ,ďчϵ͘ϱŐͬĚ>͕ŶŽZƚƌĂŶƐĨƵƐŝŽŶŝŶƉƌŝŽƌϴϰĚĂLJƐ Primary Endpoints Cohort 2: Transfusion Dependent (n = 20) ƒ Average of 2-4 RBC units / 4 weeks over 12 weeks Anemia Only Cohorts 1 & 3a: ƒ шнϭ͘ϱ
Acceleron Pharma — Investor Presentation (January 2019) on 6ix